請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/102179完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林亮音 | zh_TW |
| dc.contributor.advisor | Liang-In Lin | en |
| dc.contributor.author | 李政德 | zh_TW |
| dc.contributor.author | Cheng-Te Lee | en |
| dc.date.accessioned | 2026-03-18T16:10:36Z | - |
| dc.date.available | 2026-03-19 | - |
| dc.date.copyright | 2026-03-18 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-07-30 | - |
| dc.identifier.citation | Reference
Döhner, H., D.J. Weisdorf, and C.D. Bloomfield, Acute Myeloid Leukemia. New England Journal of Medicine, 2015. 373(12): p. 1136-1152. Appelbaum, F.R., et al., Age and acute myeloid leukemia. Blood, 2006. 107(9): p. 3481-5. Heiblig, M., et al., Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience. Mediterr J Hematol Infect Dis, 2016. 8(1): p. e2016009. Daver, N., et al., New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J, 2020. 10(10): p. 107. Lancet, J.E., et al., CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol, 2018. 36(26): p. 2684-2692. Wei, A.H., et al., Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol, 2019. 37(15): p. 1277-1284. Mecklenbrauck, R. and M. Heuser, Resistance to targeted therapies in acute myeloid leukemia. Clin Exp Metastasis, 2023. 40(1): p. 33-44. Mishra, S.K., S.E. Millman, and L. Zhang, Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood, 2023. 141(10): p. 1119-1135. Niu, J., D. Peng, and L. Liu, Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Front Oncol, 2022. 12: p. 896426. HG, B., Profiles of Drug Substances, Excipients, and Related Methodology. 2009, Elsevier Academic Press. Rowe, J.M., The "7+3" regimen in acute myeloid leukemia. Haematologica, 2022. 107(1): p. 3. Jin, G., et al., FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun, 2009. 390(3): p. 1001-6. MV-4-11. ATCC: https://www.atcc.org/products/crl-9591. 林萍平, 化療藥物Ara-C抗藥性細胞株MV4-11R的建立及其特性研究, in 醫學檢驗暨生物技術學系. 2013, 國立台灣大學: 台灣. Ko, Y.C., et al., Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib. Int J Mol Sci, 2019. 20(5): p. 1230. Martínez-Reyes, I. and N.S. Chandel, Cancer metabolism: looking forward. Nature Reviews Cancer, 2021. 21(10): p. 669-680. McKeown, S.R., Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol, 2014. 87(1035): p. 20130676. Lapa, B., et al., Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target. Med Oncol, 2020. 37(8): p. 72. Farge, T., et al., Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discov, 2017. 7(7): p. 716-735. Stuani, L., et al., Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med, 2021. 218(5). Liu, L., et al., High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid Leukemia. Cancers (Basel), 2022. 14(3). de Beauchamp, L., E. Himonas, and G.V. Helgason, Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia, 2022. 36(1): p. 1-12. Zhao, Z., et al., The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. Cancers (Basel), 2022. 15(1). Alshamleh, I., et al., PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Leukemia, 2023. 37(12): p. 2367-2382. Rodriguez-Zabala, M., et al., Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity. Blood Adv, 2023. 7(18): p. 5382-5395. Su, Y., et al., The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia. Cancer Res, 2024. 84(7): p. 1084-1100. Woodley, K., et al., Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Nat Commun, 2023. 14(1): p. 2132. Lu, M.J., et al., SLC25A51 decouples the mitochondrial NAD(+)/NADH ratio to control proliferation of AML cells. Cell Metab, 2024. 36(4): p. 808-821.e6. Holeček, M., Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid. Nutrients, 2022. 14(9). 吳潔雯, 探討具抗藥性之FLT3-ITD急性骨髓性白血病代謝機制的改變, in 醫學檢驗暨生物技術學系. 2018, 國立台灣大學: 台灣. Jeong, S., et al., High Fructose Drives the Serine Synthesis Pathway in Acute Myeloid Leukemic Cells. Cell Metab, 2021. 33(1): p. 145-159.e6. Zhang, D., et al., 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett, 2014. 355(2): p. 176-83. Pajak, B., et al., 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents. Int J Mol Sci, 2019. 21(1). Chen, X., et al., Novel therapeutic perspectives for wet age-related macular degeneration: RGD-modified liposomes loaded with 2-deoxy-D-glucose as a promising nanomedicine. Biomed Pharmacother, 2024. 175: p. 116776. Tataranni, T. and C. Piccoli, Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications. Oxid Med Cell Longev, 2019. 2019: p. 8201079. Parvathaneni, V., et al., Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes. Int J Mol Sci, 2021. 22(9). Fiorillo, M., et al., Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death Differ, 2021. 28(9): p. 2797-2817. Ngwalero, P., et al., Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrob Agents Chemother, 2021. 65(11): p. e0239920. Rathore, R., C.R. Schutt, and B.A. Van Tine, PHGDH as a mechanism for resistance in metabolically-driven cancers. Cancer Drug Resist, 2020. 3(4): p. 762-774. Arlt, B., et al., Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect. J Enzyme Inhib Med Chem, 2021. 36(1): p. 1282-1289. Rathore, R. and B. Van Tine, Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma. Mol Cell Oncol, 2021. 8(3): p. 1902250. Lindauer, M. and A. Hochhaus, Dasatinib. Recent Results Cancer Res, 2018. 212: p. 29-68. Powers, T., The origin story of rapamycin: systemic bias in biomedical research and cold war politics. Mol Biol Cell, 2022. 33(13). Dumont, F.J. and Q. Su, Mechanism of action of the immunosuppressant rapamycin. Life Sci, 1996. 58(5): p. 373-95. DCIC, B.K.-L., About NIH LINCS. 2024. Warnes, G., Annexin-V. 2019, University of London: The United Kingdom. p. http://www.icms.qmul.ac.uk/flowcytometry/uses/apoptosis/annexin-v/. Chen, Y., et al., NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia. Cell Death Discov, 2023. 9(1): p. 208. Logan, A., et al., Assessing the Mitochondrial Membrane Potential in Cells and In Vivo using Targeted Click Chemistry and Mass Spectrometry. Cell Metab, 2016. 23(2): p. 379-85. Spillier, Q., et al., Unravelling the Allosteric Targeting of PHGDH at the ACT-Binding Domain with a Photoactivatable Diazirine Probe and Mass Spectrometry Experiments. Molecules, 2021. 26(2). Tajan, M., et al., Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nat Commun, 2021. 12(1): p. 366. Récher, C., et al., Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005. 105(6): p. 2527-34. Garciaz, S., et al., Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1. Br J Haematol, 2025. 林郁蓁, 探討XPO1抑制劑與PI3K/mTOR雙重抑制劑Omipalisib在急性骨髓性白血病中的協同作用, in 醫學院醫學檢驗暨生物技術學系. 2024, 國立台灣大學: 台灣. Fiedler, W., et al., A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. Br J Haematol, 2020. 190(3): p. e169-e173. León-Annicchiarico, C.L., et al., ATF4 mediates necrosis induced by glucose deprivation and apoptosis induced by 2-deoxyglucose in the same cells. Febs j, 2015. 282(18): p. 3647-58. Faruqi A, T.P. Cytarabine. 2023 2023 Aug 8; Available from: https://www.ncbi.nlm.nih.gov/books/NBK557680/. Muley, P., A. Olinger, and H. Tummala, 2-Deoxyglucose induces cell cycle arrest and apoptosisin colorectal cancer cells independent of its glycolysis inhibition. Nutr Cancer, 2015. 67(3): p. 514-22. Kreitz, J., et al., Metabolic Plasticity of Acute Myeloid Leukemia. Cells, 2019. 8(8). Feng, L., et al., Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia. Front Oncol, 2023. 13: p. 1244280. Yang, Y., J. Pu, and Y. Yang, Glycolysis and chemoresistance in acute myeloid leukemia. Heliyon, 2024. 10(15): p. e35721. Romo-González, M., C. Ijurko, and Á. Hernández-Hernández, Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison. Front Immunol, 2022. 13: p. 889875. Jiang, J., et al., Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes. Immunotargets Ther, 2023. 12: p. 135-147. Lancet, J.E., et al., Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood, 2014. 123(21): p. 3239-46. Daver, N., et al., New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer Journal, 2020. 10(10): p. 107. Arwanih, E.Y., et al., Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review. Cureus, 2022. 14(12): p. e33165. Di Francia, R., et al., Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. Cancers (Basel), 2021. 13(5). Galmarini, C.M., et al., Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res, 2002. 26(7): p. 621-9. Kathawala, R.J., et al., Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin J Cancer, 2014. 33(5): p. 223-30. Ko Y-C, e.a., Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib. International Journal of Molecular Sciences., 2019. 20(5). Chen, X., et al., Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis, 2022. 13(11): p. 974. Yu, J.S. and W. Cui, Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development, 2016. 143(17): p. 3050-60. Ward, P.S. and C.B. Thompson, Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol, 2012. 4(7): p. a006783. Lum, J.J., et al., The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev, 2007. 21(9): p. 1037-49. Nepstad, I., et al., The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int J Mol Sci, 2020. 21(8). Castro, I., B. Sampaio-Marques, and P. Ludovico, Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. Cells, 2019. 8(9). Cheng, C., et al., Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother, 2021. 142: p. 111652. Song, K., et al., Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia. Oncol Lett, 2016. 12(1): p. 334-342. Takubo, K., et al., Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell, 2010. 7(3): p. 391-402. Panina, S.B., J. Pei, and N.V. Kirienko, Mitochondrial metabolism as a target for acute myeloid leukemia treatment. Cancer Metab, 2021. 9(1): p. 17. Bjelosevic, S., et al., Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. Cancer Discov, 2021. 11(6): p. 1582-1599. Ducker, G.S. and J.D. Rabinowitz, One-Carbon Metabolism in Health and Disease. Cell Metab, 2017. 25(1): p. 27-42. Tseng, C.-Y., et al., Modulating Metabolic Reprogramming By Phosphoglycerate Dehydrogenase (PHGDH) Inhibitors in Omipalisib-Refractory AML. Blood, 2023. 142(Supplement 1): p. 1432-1432. Zhong, J., et al., PHGDH is Key to a Prognostic Multigene Signature and a Potential Therapeutic Target in Acute Myeloid Leukemia. J Cancer, 2024. 15(9): p. 2538-2548. Newman, A.C. and O.D.K. Maddocks, Serine and Functional Metabolites in Cancer. Trends Cell Biol, 2017. 27(9): p. 645-657. Alvarez-Calderon, F., et al., Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res, 2015. 21(6): p. 1360-72. Sipula, I.J., N.F. Brown, and G. Perdomo, Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism, 2006. 55(12): p. 1637-44. Zhang, X.D., et al., Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res, 2006. 26(5a): p. 3561-6. Larrue, C., et al., Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. Mol Cancer Ther, 2015. 14(10): p. 2364-73. Strandberg, A.Y., et al., Comparison of normal fasting and one-hour glucose levels as predictors of future diabetes during a 34-year follow-up. Ann Med, 2013. 45(4): p. 336-40. Cheng, Y., et al., High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose. Biomed Rep, 2014. 2(2): p. 188-192. Raez, L.E., et al., A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2013. 71(2): p. 523-30. Bhatt, A.N., et al., 2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial. BMC Infect Dis, 2022. 22(1): p. 669. Hansen, I.L., M.M. Levy, and D.S. Kerr, The 2-deoxyglucose test as a supplement to fasting for detection of childhood hypoglycemia. Pediatr Res, 1984. 18(5): p. 490-5. Ahmad Khosravi, N., et al., A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis. J Clin Lab Anal, 2024. 38(15-16): p. e25091. Zorova, L.D., et al., Mitochondrial membrane potential. Anal Biochem, 2018. 552: p. 50-59. Dilip, A., et al., Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma. Anticancer Drugs, 2013. 24(9): p. 881-8. Aisu, Y., et al., Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch. PLoS One, 2024. 19(12): p. e0309700. Komza, M., et al., Metabolic adaptations to acute glucose uptake inhibition converge upon mitochondrial respiration for leukemia cell survival. Cell Commun Signal, 2025. 23(1): p. 47. Ajayi, T.O., M.S. Poka, and B.A. Witika, Formulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design. Sci Rep, 2024. 14(1): p. 31891. Najib Ullah, S.N.M., et al., Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel), 2023. 16(9). Solaini, G., G. Sgarbi, and A. Baracca, Oxidative phosphorylation in cancer cells. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2011. 1807(6): p. 534-542. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/102179 | - |
| dc.description.abstract | 急性骨髓性白血病（AML）是一種以血球前驅細胞異常增生為特徵的惡性疾病，會導致貧血、疲勞和感染等症狀。由於AML主要影響65歲以上的族群，年長患者對高強度化療的耐受性較低，治療上面臨如抗藥性等諸多挑戰。近期研究顯示AML細胞可透過調控細胞代謝，特別是增強糖解作用與氧化磷酸化，產生對臨床用藥的抗藥性。我們在實驗室中建立了對阿糖胞苷具抗藥性的AML細胞株MV4-11R，並觀察到相較於母株細胞MV4-11P，MV4-11R展現出更強的代謝能力。我們期望透過抑制MV4-11R的代謝以減緩其對阿糖胞苷的抗藥性。
首先，我們確認MV4-11R對阿糖胞苷具有抗藥性，並伴隨糖解作用與氧化磷酸化能力的增強。在代謝抑制藥物的初步篩選中，我們發現使用糖解抑制劑(2-脫氧-D-葡萄糖)或氧化磷酸化抑制劑(貝達喹啉)處理MV4-11R後，其細胞活性顯著下降。接著，在雙藥合併組合測試中，2-脫氧-D-葡萄糖合併貝達喹啉使MV4-11R細胞型態顯著改變。當分別與阿糖胞苷合併使用時，2-脫氧-D-葡萄糖、貝達喹啉皆可以顯著降低MV4-11R細胞活性，誘導細胞週期停滯於G0/G1、並降低細胞代謝，如ATP產量、乳酸產量、活性氧水平及粒線體膜電位。進一步進行三藥合併測試，亦即2-脫氧-D-葡萄糖、貝達喹啉與阿糖胞苷合併處理MV4-11R，相較於雙藥合併的作用，細胞凋亡與死亡更多，細胞停滯於G0/G1期更多，細胞代謝作用更進一步地下降。雖然這些調控效果可能僅限於分子層面，但這些結果突顯了代謝調控在減緩AML對cytarabine抗藥性中的潛力。 | zh_TW |
| dc.description.abstract | Acute myeloid leukemia (AML) is a malignant hematological disease characterized by the abnormal proliferation of hematopoietic precursor cells, leading to symptoms such as anemia, fatigue, and increased susceptibility to infections. AML primarily affects individuals over the age of 65, and these elderly patients often have poor tolerance to intensive chemotherapy, presenting many therapeutic challenges, including the development of drug resistance. Recent studies have revealed that AML cells may acquire resistance to chemotherapeutic drugs by reprogramming cellular metabolism, particularly through upregulation of glycolysis and oxidative phosphorylation (OXPHOS). In our laboratory, we previously established a cytarabine-resistant AML cell line, MV4-11R, which exhibits enhanced metabolism compared to its parental counterpart, MV4-11P. To resolve this cytarabine resistance, we aim to target the metabolic plasticity of MV4-11R cells to mitigate their chemoresistance.
First, we confirmed that MV4-11R cells exhibited resistance to cytarabine, which was associated with an increased reliance on glycolysis and oxidative phosphorylation (OXPHOS). Next, a preliminary screening of metabolic inhibitors revealed that treatment with either the glycolytic inhibitor, 2-deoxy-D-glucose (2-DG), or the OXPHOS inhibitor, bedaquiline, significantly reduced the viability of MV4-11R cells. In subsequent combination treatment assays, combination of 2-DG and bedaquiline induced significant change in cellular morphology of MV4-11R. When administered separately with cytarabine, 2-DG and bedaquiline significantly reduced MV4-11R viability, induced G0/G1 cell cycle arrest, and suppressed ATP production, lactate production, reactive oxygen species (ROS) levels, and mitochondrial membrane potential (ΔΨm). Further investigation using triple drug combination therapy with 2-DG, bedaquiline, and cytarabine demonstrated that compared to dual-drug treatments, it was more effective in inducting apoptosis and cell death with pronounced G0/G1 arrest, and further inhibition of metabolic activities. Although these regulatory effects may be confined to the molecular level, our findings underscore the therapeutic potential of metabolic modulation in overcoming cytarabine resistance in AML. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-03-18T16:10:36Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2026-03-18T16:10:36Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | Acknowledgements i
摘要 ii Abstract iii Table of Contents v List of Figures x List of Tables xi List of Abbreviations xii Chapter 1. Introduction 1 1.1 Acute Myeloid Leukemia (AML) 1 1.1.1 Introduction to AML 1 1.1.2 Current therapy against AML 2 1.2 Cytarabine (AraC) 4 1.2.1 Introduction to AraC 4 1.2.2 Challenges in cytarabine therapy 4 1.2.3 MV4-11 and cytarabine resistance MV4-11 5 1.3 Cellular metabolism 6 1.3.1 Glycolysis and Mitochondrial Oxidative Phosphorylation (OXPHOS) 6 1.3.2 Glycolysis-associated and OXHPOS-associated resistance in AML 8 1.3.3 Serine synthesis 10 1.4 Metabolic inhibitors and other inhibitors 11 1.4.1 Glycolysis inhibitors 11 1.4.2 OXPHOS inhibitors 13 1.4.3 PHGDH inhibitors 13 1.4.4 Other profile inhibitors 14 Chapter 2. Purpose 16 Chapter 3. Materials and Methods 17 3.1 Materials 17 3.1.1 Cell lines 17 3.1.2 Equipment 17 3.2 Methods 22 3.2.1 Cell culture 22 3.2.2 Cell proliferation curve 22 3.2.3 CCK8 cell viability assay 23 3.2.4 Lactate production assay 24 3.2.5 ATP level assay 25 3.2.6 ROS level assay 26 3.2.7 Mitochondrial membrane potential assay 27 3.2.8 Apoptosis analysis 29 3.2.9 Cell cycle analysis 30 3.2.10 RNA extraction 32 3.2.11 Reverse transcription – polymerase chain reaction(RT-PCR) 34 3.2.12 Quantitative polymerase chain reaction(qPCR) 34 3.2.13 Analysis on SigCom LINCS 35 3.2.14 Cellular Morphology 36 3.2.15 Statistical methods 37 Chapter 4. Results 39 4.1 MV4-11R exhibited resistance to cytarabine with increased proliferation and more robust metabolism in comparison to MV4-11P. 39 4.1.1 MV4-11R was resistant to cytarabine in contrast to MV4-11P 39 4.1.2 MV4-11R had increased proliferation in contrast to MV4-11P 39 4.1.3 MV4-11R had increased lactate production in contrast to MV4-11P 40 4.1.4 MV4-11R showed elevated ATP production in contrast to MV4-11P 40 4.1.5 MV4-11R shared similar ROS level with MV4-11P & R 41 4.1.6 MV4-11R harbored lower mitochondrial membrane potential in contrast to MV4-11P 41 4.2 MV4-11R was sensitive to some metabolic inhibitors. 44 4.2.1 MV4-11R was more sensitive to glycolysis inhibitors 2-DG rather than DCA 44 4.2.2 MV4-11R showed similar sensitivity to bedaquiline with MV4-11P. 44 4.2.3 Both MV4-11P & R were sensitive to inhibitors of serine synthesis 45 4.3 MV4-11R was also sensitive to other inhibitors, such as selinexor and dasatinib 49 4.3.1 MV4-11R was more sensitive to dasatinib than MV4-11P, while both cell lines are not sensitive to rapamycin 49 4.3.2 MV4-11R was more sensitive to XPO1 inhibitors than MV4-11P 50 4.4 Combination of 2-DG or bedaquiline and cytarabine significantly reduced cell viability in MV4-11R 53 4.4.1 2-DG showed superior additive effect with bedaquiline 53 4.4.2 2-DG and bedaquiline showed superior additive effect with cytarabine among various metabolic inhibitors. 54 4.4.3 Dasatinib showed no synergy with cytarabine 54 4.5 Combination of 2-DG or bedaquiline with cytarabine both significantly increased apoptosis and cell death in MV4-11R 59 4.6 Combination of 2-DG or bedaquiline with cytarabine both resulted in cell cycle arrest at G0/G1 phase in MV4-11R 63 4.7 Combination of 2-DG and cytarabine significantly restrained cellular metabolism in MV4-11R 66 4.7.1 2-DG depletes ATP production in MV4-11R 66 4.7.2 2-DG reduced lactate production in MV4-11R 66 4.7.3 2-DG decreased ROS level in MV4-11R 67 4.7.4 2-DG lowered mitochondrial membrane potential (MMP) in MV4-11R 67 4.7.5 BBQ depleted ATP production in MV4-11R 67 4.7.6 Selinexor did not inhibit ATP production in MV4-11R 68 4.8 Combination of 2-DG and cytarabine showed no effect on the expression of glycolysis-associated genes in MV4-11R. 72 4.9 Combination of 2-DG, bedaquiline and cytarabine resulted in significant decrease in cellular metabolism 76 4.10 Combination of 2-DG, bedaquiline and cytarabine resulted in significant increase in cell death, apoptosis and cell cycle arrest at G0/G1 phase in MV4-11R 80 4.11 Combination of 2-DG, bedaquiline and cytarabine led to increased formation of cytoplasmic vacuoles in MV4-11R 85 Chapter 5. Discussion 90 Chapter 6. Reference 101 Appendix Figure 112 Appendix Table 133 | - |
| dc.language.iso | en | - |
| dc.subject | 急性骨髓性白血病 | - |
| dc.subject | 白血病代謝 | - |
| dc.subject | 代謝調節 | - |
| dc.subject | 阿糖胞苷 | - |
| dc.subject | 阿糖胞苷抗性 | - |
| dc.subject | 2-脫氧-D-葡萄糖 | - |
| dc.subject | 貝達喹啉 | - |
| dc.subject | acute myeloid leukemia | - |
| dc.subject | leukemic metabolism | - |
| dc.subject | cytarabine | - |
| dc.subject | metabolic modulation, | - |
| dc.subject | cytarabine-resistance, | - |
| dc.subject | 2-deoxy-glucose | - |
| dc.subject | bedaquiline | - |
| dc.title | 透過調節代謝緩解MV4-11細胞對Cytarabine的抗性 | zh_TW |
| dc.title | Alleviate the Resistance of MV4-11 to Cytarabine by Modulating Metabolism | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 歐大諒;胡忠怡;郭靜穎;蘇剛毅 | zh_TW |
| dc.contributor.oralexamcommittee | Da-Liang Ou;Zhong-Yi Hu;Ching-Ying Kuo;Kang-Yi Su | en |
| dc.subject.keyword | 急性骨髓性白血病,白血病代謝代謝調節阿糖胞苷阿糖胞苷抗性2-脫氧-D-葡萄糖貝達喹啉 | zh_TW |
| dc.subject.keyword | acute myeloid leukemia,leukemic metabolismcytarabinemetabolic modulation,cytarabine-resistance,2-deoxy-glucosebedaquiline | en |
| dc.relation.page | 138 | - |
| dc.identifier.doi | 10.6342/NTU202502976 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2025-07-31 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學系 | - |
| dc.date.embargo-lift | 2026-03-19 | - |
| 顯示於系所單位： | 醫學檢驗暨生物技術學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf | 76.91 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。